

## **IAS Panel for Global Recommendations for the Management of Dyslipidemia**

**Scott M. Grundy** – Chair of the IAS Panel for Global Recommendations for the Management of Dyslipidemia, Professor of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Consultant: Merck, Johnson and Johnson, Pfizer, Sanofi Aventis

**Hidenori Arai** – Professor, Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan

Honoraria: Daiichi Sankyo, Kowa and Merck Sharp & Dohme

**Philip Barter** – President, International Atherosclerosis Society

Research Grants: Merck, Pfizer

Honoraria: Amgen, AstraZeneca, ISIS, Kowa, Merck, Novartis, Pfizer, Roche

Advisory Board: AstraZeneca, CSL, Kowa, Lilly, Merck, Novartis, Pfizer, Roche

**Thomas P. Bersot** – Associate Investigator and Professor of Medicine, J. David Gladstone Institutes, University of California San Francisco, San Francisco, California, USA

Consultant: AbbVie, Aegerion Pharmaceuticals, Genzyme Pharmaceuticals, Merck and Co.

Stock Ownership: Merck and Co. (spouse)

Honoraria: AbbVie, Aegerion, AstraZeneca, Merck and Co.

**D. John Betteridge** – Consultant Physician, University College Hospital London and Emeritus Professor of Endocrinology and Metabolism, University College London, London, UK

Honoraria: Amgen, Merck Sharp & Dohme, Pfizer and Kowa, Sanofi, Takeda

**Rafael Carmena** – Professor Emeritus of Internal Medicine and Endocrinology, University of Valencia, Spain, General Director of the Clinical Research Institute (INCLIVA), University Hospital, Valencia, Spain

No conflict of interests

**Ada Cuevas** – Department of Nutrition, Clínica Las Condes, Santiago, Chile

Advisory boards: Amgen, Merck Sharp & Dohme

Honoraria: Merck, Sanofi, Merck Sharp & Dohme

**Michael H. Davidson** – Professor, Director of the Lipid Clinic, The University of Chicago, Pritzker School of Medicine, Chicago, IL, USA

Speakers' Bureau: Merck

Advisory Board/Consultant: Abbvie, Amgen, AstraZeneca, Daiichi-Sankyo, Esperion, Lipidemx, Merck, Vindico

**Jacques Genest** – Cardiologist, Professor, Faculty of Medicine, McGill University, Novartis Chair in Medicine at McGill, Scientific Director, Center for Innovative Medicine, McGill University Health Center/Royal Victoria Hospital, Montreal, QC, Canada

Advisory Board: Amgen, Merck, Roche, Sanofi

Speakers Bureau: Amgen, Merck

Steering Committee: AstraZeneca (JUPITER), Merck (IMPROVE-IT), Novartis Pharmaceuticals (CANTOS)

Involved in Clinical trials: Amgen (AMG145), Merck Sharp & Dohme (REVEAL), Novartis (ACCELERATE)

**Y. Antero Kesäniemi** – Professor of Internal Medicine, Emeritus, Institute of Clinical Medicine, Department of Medicine, University of Oulu and Clinical Research Center, Oulu University Hospital, Oulu, Finland

Research Grant: Merck Sharp & Dohme

Honoraria: Abbott, Merck Sharp & Dohme, Novo Nordisk

Ownership: some Orion Pharma stocks

Advisory Board: Merck Sharp & Dohme

**Shaukat Sadikot** – Diabetes India, Mumbai, India

No conflict of interest

**Raul D. Santos** – Director Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Associate Professor of Cardiology, University of Sao Paulo, Brazil

Consultant/advisory board: Abbott, Aegerion, Amgen, AstraZeneca, Biolab, Bristol-Myers Squibb, Eli Lilly, Merck, Novo Nordisk, Pfizer, Roche

Honoraria speaker engagements: AstraZeneca, Biolab, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer

**Andrey V. Susekov** – Associate Professor, Laboratory of Clinical Lipidology, Department of Atherosclerosis, Cardiology Research Complex, Moscow, Russia

Honoraria: Abbott, Amgen, AstraZeneca, Merck Sharp & Dohme, Pfizer, Krka and Gedeon Richter

**Rody G. Sy** – Professor and Chair, Department of Medicine, University of the Philippines College of Medicine, Manila, Philippines

Honoraria: Abbott, Astra, LRI-Therapharma, Merck Sharp & Dohme, Novartis, Pfizer and Sanofi

Advisory Committee: Amgen, Astra, GSK, Merck Sharp & Dohme, Pfizer and Sanofi

**S. Lale Tokgözoğlu** – Professor of Cardiology, Hacettepe University, Ankara, Turkey

Cad: 9, Ankara, Turkey

Honoraria: Abbott, Actelion, Astra, Bayer, Boehringer, Daiichi-Sankyo, Novartis, Pfizer, Roche, Sanofi Servier

Advisory board: Kowa and Merck Sharp & Dohme

**Gerald F. Watts** – Winthrop Professor, Cardiometabolic Medicine, Cardiometabolic Clinic, Royal Perth Hospital, School of Medicine and Pharmacology, The University of Western Australia, Australia

Honoraria: Abbott, Amgen and Sanofi, Genfit, Kowa, Merck Sharp & Dohme

**Dong Zhao** – Deputy Director & Professor, Beijing Institute of Heart, Lung & Blood Vessel Diseases, Capital Medical University Beijing Anzhen Hospital, Beijing, China

Honoraria: Kowa, Pfizer